TNFSF10 and Miyoshi myopathy: This is a highly intriguing finding, since it points to the possibility that, if applied together, α-TOS and TRAIL will efficiently and selectively kill MM cells while protecting the neighbouring nonmalignant mesothelial cells of the pleural or peritoneal cavity (cfFigure 4).